CRISPR Therapeutics Advances Gene-Editing Treatments Towards Late-Stage Trials Amidst Growing CASGEVY Demand
Rapid Read

CRISPR Therapeutics Advances Gene-Editing Treatments Towards Late-Stage Trials Amidst Growing CASGEVY Demand

What's Happening? CRISPR Therapeutics is preparing to move several experimental gene-editing treatments into late-stage trials, according to executives at a Jefferies fireside chat. The company's CTX310, zugo-cel, and CTX611 programs are anticipated to enter late-stage trials within approximately a
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.